N A Marskaya

Plain English
This study looked at the effectiveness of two treatments for stroke caused by a blockage in the middle cerebral artery: endovascular thrombectomy (EVT) alone versus EVT combined with intravenous thrombolysis (IVT). Researchers analyzed data from 801 patients and found that those who received IVT were more likely to have successful first-pass treatment (49% vs. 40%) and experienced lower in-hospital mortality rates (23% vs. 34%). This matters because it shows that adding IVT to EVT can lead to better outcomes for stroke patients while maintaining a similar risk for complications. Who this helps: This benefits stroke patients and healthcare providers involved in their treatment.

Plain English
This study looked at the use of a new drug called tenecteplase for treating ischemic stroke in three patients in Russia. All three patients showed major improvements in their neurological symptoms within an hour of receiving the drug, and there were no increases in stroke damage after 24 hours. This matters because it highlights that tenecteplase is a safe and effective option for stroke treatment, leading to better patient outcomes. Who this helps: This helps stroke patients and doctors treating them.

Plain English
This study looked at the use of the drug Fortelyzin to treat patients who had an acute ischemic stroke (AIS) when they received treatment between 4.5 and 24 hours after their symptoms started. Researchers found that 61% of patients treated within the first 4.5 hours had a good recovery, while 65% of those treated later also had a good recovery, showing that treatment is still effective even when started later. The rates of serious complications were similar in both groups, indicating that Fortelyzin is a safe option for stroke patients, regardless of when they receive treatment. Who this helps: This helps stroke patients who may not get to the hospital within the first few hours of their symptoms.

Plain English
This study looked at how safe and effective a drug called Fortelyzin is for people having an acute ischemic stroke, specifically when used during treatments that involve both thrombolysis and thrombectomy. Out of 1,116 patients, 38% had a good recovery after 90 days, while 29% died in that time. The findings are important because they show that Fortelyzin can be a useful option in treating stroke patients in everyday healthcare settings. Who this helps: This benefits doctors and patients dealing with acute ischemic strokes.

Plain English
This research studied how well the THRIVE scale predicts the outcomes of older patients (60 years and up) with acute ischemic stroke (AIS) who were treated with a new drug called staphylokinase, compared to a standard treatment called alteplase. The analysis showed that the THRIVE scale is a reliable tool for predicting health outcomes; for instance, its accuracy in predicting 90-day all-cause mortality was 80% for staphylokinase and 76% for alteplase. This is important because it can help doctors better gauge how patients might recover after treatment, ensuring that older patients receive the best possible care. Who this helps: Patients aged 60 and older who have had a stroke.

Plain English
This study looked at how new treatments for ischemic stroke (IS) are being used in Russia from 2015 to early 2025. Researchers found that more patients are getting treated quickly after symptoms start, with those admitted within 4.5 hours rising from 23% in 2015 to 31% in 2024. The use of reperfusion treatments, like IVT and thrombectomy, also increased significantly, leading to a reduction in mortality rates from 16.8% in 2015 to 12.6% in 2025. This matters because faster and better treatment can help more people survive strokes and recover their abilities. Who this helps: This helps patients who suffer from strokes and improve outcomes through timely medical interventions.

Plain English
This study looked at how using teleconsulting in primary vascular units (tele-PVUs) improved access to specialized stroke treatment in Russia. It found that 9.8% of stroke patients treated in these units received thrombolytic therapy, which is higher than the national average, and the time from when symptoms started to when treatment began was also reduced. This is important because it means more patients in rural areas can get life-saving treatment faster. Who this helps: Patients in rural areas who suffer from ischemic strokes.

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

Plain English
This study looked at the use of a drug called Revelisa to treat people who had ischemic strokes, which happen when blood flow to the brain is blocked. Researchers treated 550 patients and found that about 45% showed significant improvement in their condition one day after treatment. Additionally, 68.5% of patients had good recovery by the time they were discharged from the hospital after 90 days. Who this helps: This research benefits patients experiencing ischemic strokes and their healthcare providers by showing that Revelisa can effectively reduce symptoms and improve recovery.

Plain English
This study looked at the use of a drug called Revelisa for treating ischemic stroke patients in real-life hospital settings. Out of 223 patients treated, 7.1% experienced complications from bleeding in the brain, and 13.9% died during their hospital stay. After treatment, nearly half of the patients (48.2%) showed good recovery at discharge, which is comparable to results from other treatments like alteplase. Who this helps: Patients who suffer from ischemic strokes.